CompletedNot Applicable

A Longitudinal Study of Hermansky-Pudlak Syndrome Pulmonary Fibrosis

United States55 participantsStarted 2015-03

Plain-language summary

Hermansky-Pudlak Syndrome (HPS) is a rare genetic disease that is associated with oculocutaneous albinism, bleeding, granulomatous colitis, and pulmonary fibrosis in some subtypes, including HPS-1, HPS-2, and HPS-4. Pulmonary fibrosis causes shortness of breath and progressive decline in lung function. In HPS patients with at-risk subtypes, almost all adults eventually develop fatal pulmonary fibrosis unless they undergo lung transplantation. The purpose of this study is to identify the earliest measurable pulmonary disease activity in individuals at-risk for HPS pulmonary fibrosis. The study also aims to develop biomarkers that will aid in understanding of the causes of HPS pulmonary fibrosis and facilitate more rapid conduct of therapeutic trials in HPS patients with mild pulmonary disease in the future.

Who can participate

Age range12 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Individuals ages 12-90 years with confirmed diagnosis of HPS as defined by verification of reduced or absent platelet dense granules by electron microscopy and/or genetic diagnosis * Ability to provide informed consent, or consent of parent/guardian and assent for minors Exclusion Criteria: * Status-post lung transplantation * Perceived unsuitability for participation in the study in the opinion of the investigator

What they're measuring

Chest CT scan

Timeframe: change in CT Scan from baseline to 2.5 years

Trial details

NCT IDNCT02368340

SponsorVanderbilt University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-10-15

View on ClinicalTrials.gov More Hermansky Pudlak Syndrome trials